$OMER
OMEROS CORP

2020 Q2 Form 10-Q Financial Statement

#000155837020010182 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $13.53M $26.75M
YoY Change -49.43% 1516.5%
Cost Of Revenue $147.0K $55.00K
YoY Change 167.27% -52.59%
Gross Profit $13.38M $26.70M
YoY Change -49.87% 1634.76%
Gross Profit Margin 98.91% 99.79%
Selling, General & Admin $16.93M $16.93M
YoY Change 0.0% 32.89%
% of Gross Profit 126.5% 63.41%
Research & Development $24.13M $19.11M
YoY Change 26.29% -1.57%
% of Gross Profit 180.32% 71.57%
Depreciation & Amortization $410.0K $450.0K
YoY Change -8.89% 114.29%
% of Gross Profit 3.06% 1.69%
Operating Expenses $24.13M $19.11M
YoY Change 26.29% -40.79%
Operating Profit -$27.68M -$9.338M
YoY Change 196.42% -69.5%
Interest Expense $5.978M $5.530M
YoY Change 8.1% 50.44%
% of Operating Profit
Other Income/Expense, Net $364.0K $415.0K
YoY Change -12.29% -30.49%
Pretax Income -$33.29M -$14.45M
YoY Change 130.38% -57.12%
Income Tax
% Of Pretax Income
Net Earnings -$33.29M -$14.45M
YoY Change 130.36% -57.11%
Net Earnings / Revenue -246.08% -54.02%
Basic Earnings Per Share -$0.61
Diluted Earnings Per Share -$0.61 -$294.4K
COMMON SHARES
Basic Shares Outstanding 54.51M 49.06M shares
Diluted Shares Outstanding 54.51M

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.10M $31.80M
YoY Change -49.37% -64.03%
Cash & Equivalents $2.000M $4.000M
Short-Term Investments $14.10M $27.90M
Other Short-Term Assets $5.200M $4.400M
YoY Change 18.18% -30.16%
Inventory $1.892M $1.187M
Prepaid Expenses
Receivables $15.70M $28.40M
Other Receivables $86.00K $134.0K
Total Short-Term Assets $38.93M $65.94M
YoY Change -40.97% -31.67%
LONG-TERM ASSETS
Property, Plant & Equipment $3.109M $4.183M
YoY Change -25.68% 71.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.100M $2.300M
YoY Change -8.7% -68.92%
Total Long-Term Assets $31.76M $23.82M
YoY Change 33.36% 141.91%
TOTAL ASSETS
Total Short-Term Assets $38.93M $65.94M
Total Long-Term Assets $31.76M $23.82M
Total Assets $70.69M $89.76M
YoY Change -21.25% -15.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.507M $6.260M
YoY Change 35.89% -47.17%
Accrued Expenses $25.84M $31.78M
YoY Change -18.69% 165.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.200M $1.100M
YoY Change 9.09% 80.92%
Total Short-Term Liabilities $38.05M $40.67M
YoY Change -6.46% 66.41%
LONG-TERM LIABILITIES
Long-Term Debt $164.5M $155.1M
YoY Change 6.06% 19.54%
Other Long-Term Liabilities $29.50M $24.30M
YoY Change 21.4% 185.88%
Total Long-Term Liabilities $194.0M $179.4M
YoY Change 8.14% 38.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.05M $40.67M
Total Long-Term Liabilities $194.0M $179.4M
Total Liabilities $232.0M $220.0M
YoY Change 5.45% 42.68%
SHAREHOLDERS EQUITY
Retained Earnings -$796.9M -$688.9M
YoY Change 15.68% 17.34%
Common Stock $635.7M $558.6M
YoY Change 13.79% 115085.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$161.3M -$130.3M
YoY Change
Total Liabilities & Shareholders Equity $70.69M $89.76M
YoY Change -21.25% -15.6%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$33.29M -$14.45M
YoY Change 130.36% -57.11%
Depreciation, Depletion And Amortization $410.0K $450.0K
YoY Change -8.89% 114.29%
Cash From Operating Activities -$37.60M -$16.59M
YoY Change 126.64% -46.33%
INVESTING ACTIVITIES
Capital Expenditures -$140.0K -$100.0K
YoY Change 40.0% -52.38%
Acquisitions
YoY Change
Other Investing Activities $32.74M $15.31M
YoY Change 113.85% -210.14%
Cash From Investing Activities $32.59M $15.21M
YoY Change 114.27% -207.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -150.0K 1.310M
YoY Change -111.45% -97.2%
NET CHANGE
Cash From Operating Activities -37.60M -16.59M
Cash From Investing Activities 32.59M 15.21M
Cash From Financing Activities -150.0K 1.310M
Net Change In Cash -5.160M -70.00K
YoY Change 7271.43% -104.12%
FREE CASH FLOW
Cash From Operating Activities -$37.60M -$16.59M
Capital Expenditures -$140.0K -$100.0K
Free Cash Flow -$37.46M -$16.49M
YoY Change 127.17% -46.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001285819
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54200810
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54515858
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34475
dei Entity Registrant Name
EntityRegistrantName
OMEROS CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1663741
dei Local Phone Number
LocalPhoneNumber
676-5000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OMER
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3084000
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54518358
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1964000
dei Entity Address Address Line1
EntityAddressAddressLine1
201 Elliott Avenue West
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98119
dei City Area Code
CityAreaCode
206
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
14124000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
57704000
CY2020Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
15780000
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
35185000
CY2020Q2 us-gaap Inventory Net
InventoryNet
1892000
CY2019Q4 us-gaap Inventory Net
InventoryNet
1147000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5167000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6625000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
38927000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
103745000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3109000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3829000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26603000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27082000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1154000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1154000
CY2020Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
896000
CY2019Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1159000
CY2020Q2 us-gaap Assets
Assets
70689000
CY2019Q4 us-gaap Assets
Assets
136969000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8507000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5328000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25838000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46627000
CY2020Q2 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
3702000
CY2019Q4 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
3504000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
38047000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55459000
CY2020Q2 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
30540000
CY2019Q4 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
32318000
CY2020Q2 us-gaap Senior Long Term Notes
SeniorLongTermNotes
163372000
CY2019Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
158213000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54515858
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54200810
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
545000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
542000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
635121000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
625048000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-796936000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-734611000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-161270000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-109021000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70689000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136969000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13530000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26753000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37067000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48532000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
147000
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
55000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
414000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
186000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24132000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19108000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53043000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45363000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16931000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16928000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34967000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31560000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
41210000
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
36091000
us-gaap Costs And Expenses
CostsAndExpenses
88424000
us-gaap Costs And Expenses
CostsAndExpenses
77109000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27680000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9338000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51357000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28577000
CY2020Q2 us-gaap Interest Expense
InterestExpense
5978000
CY2019Q2 us-gaap Interest Expense
InterestExpense
5530000
us-gaap Interest Expense
InterestExpense
11880000
us-gaap Interest Expense
InterestExpense
11130000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
364000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
415000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
912000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
909000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-33294000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14453000
us-gaap Net Income Loss
NetIncomeLoss
-62325000
us-gaap Net Income Loss
NetIncomeLoss
-38798000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33294000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14453000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62325000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38798000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54513337
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49084093
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54406575
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49048432
us-gaap Profit Loss
ProfitLoss
-62325000
us-gaap Profit Loss
ProfitLoss
-38798000
us-gaap Share Based Compensation
ShareBasedCompensation
7298000
us-gaap Share Based Compensation
ShareBasedCompensation
6973000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5159000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4435000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
814000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
827000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-19405000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
5697000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
745000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1099000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1881000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1975000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-18225000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1847000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46738000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29537000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
210000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
279000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3188000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
472000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
46768000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43370000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26499000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2778000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1708000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
530000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
545000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2248000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1163000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1120000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1875000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3084000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5861000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1964000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3986000
us-gaap Interest Paid Net
InterestPaidNet
6721000
us-gaap Interest Paid Net
InterestPaidNet
6731000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
44000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
886000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 12.25pt;">Organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, addiction and immune-related diseases, including cancers. Our first drug product, OMIDRIA, is marketed in the United States (U.S.) for use during cataract surgery or intraocular lens replacement.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
16100000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51400000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-63400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46700000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 12.25pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, stock-based compensation expense and accruals for clinical trials, manufacturing of drug product and clinical drug supply and other contingencies. We base our estimates on historical experience and on various other factors, including the impact of the COVID-19 pandemic, that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13028800
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12044074
CY2020Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
15694000
CY2019Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
35074000
CY2020Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
86000
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
111000
CY2020Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
15780000
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
35185000
CY2020Q2 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
1100000
CY2019Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
1600000
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
91000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
91000
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1195000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
338000
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
606000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
718000
CY2020Q2 us-gaap Inventory Net
InventoryNet
1892000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2019Q4 us-gaap Inventory Net
InventoryNet
1147000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9958000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9864000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6849000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6035000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3109000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3829000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2020Q2 omer Accrued Contract Research Costs
AccruedContractResearchCosts
9206000
CY2019Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
24107000
CY2020Q2 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
5737000
CY2019Q4 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
10870000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3420000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3546000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3325000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3610000
CY2020Q2 us-gaap Interest Payable Current
InterestPayableCurrent
1640000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1640000
CY2020Q2 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
1629000
CY2019Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
1982000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
881000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
872000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25838000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46627000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2000000.0
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3100000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26603000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27082000
CY2020Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2314000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2973000
CY2020Q2 omer Lease Right Of Use Asset
LeaseRightOfUseAsset
28917000
CY2019Q4 omer Lease Right Of Use Asset
LeaseRightOfUseAsset
30055000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2503000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2282000
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1199000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1222000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29457000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30772000
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1083000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1546000
CY2020Q2 omer Lease Liability
LeaseLiability
34242000
CY2019Q4 omer Lease Liability
LeaseLiability
35822000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
646000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
159000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
169000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
275000
us-gaap Variable Lease Cost
VariableLeaseCost
1102000
us-gaap Variable Lease Cost
VariableLeaseCost
980000
us-gaap Sublease Income
SubleaseIncome
602000
us-gaap Sublease Income
SubleaseIncome
447000
us-gaap Operating Lease Cost
OperatingLeaseCost
3024000
us-gaap Operating Lease Cost
OperatingLeaseCost
2062000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
703000
us-gaap Lease Cost
LeaseCost
4386000
us-gaap Lease Cost
LeaseCost
3685000
us-gaap Operating Lease Payments
OperatingLeasePayments
4284000
us-gaap Operating Lease Payments
OperatingLeasePayments
3301000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
159000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
169000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
530000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
545000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
omer Number Of Options To Extend Lease
NumberOfOptionsToExtendLease
2
CY2020Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
49800000
CY2020Q2 omer Long Term Purchase Commitment Termination Fee
LongTermPurchaseCommitmentTerminationFee
18100000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2800000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
315048
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1700000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
184365
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-109021000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2712000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3476000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29031000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-131864000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3822000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-33294000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-161270000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-100156000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
108000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3374000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-24345000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-121019000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1600000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3598000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14453000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-130274000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3822000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3598000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7298000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6973000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11207931
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2034960
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.37
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
315048
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
142158
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.32
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12785685
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.87
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
41036000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12336369
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
40291000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8712170
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M24D
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
34089000

Files In Submission

Name View Source Status
0001558370-20-010182-index-headers.html Edgar Link pending
0001558370-20-010182-index.html Edgar Link pending
0001558370-20-010182.txt Edgar Link pending
0001558370-20-010182-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omer-20200630.xsd Edgar Link pending
omer-20200630x10q.htm Edgar Link pending
omer-20200630x10q005.jpg Edgar Link pending
omer-20200630x10q_htm.xml Edgar Link completed
omer-20200630xex10d1.htm Edgar Link pending
omer-20200630xex31d1.htm Edgar Link pending
omer-20200630xex31d2.htm Edgar Link pending
omer-20200630xex32d1.htm Edgar Link pending
omer-20200630xex32d2.htm Edgar Link pending
omer-20200630_cal.xml Edgar Link unprocessable
omer-20200630_def.xml Edgar Link unprocessable
omer-20200630_lab.xml Edgar Link unprocessable
omer-20200630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending